Special Issue

Next-Generation Antibiotic Strategies Against Drug-Resistant Bacteria

Message from the Guest Editors

Antimicrobial resistance (AMR) remains one of the greatest global threats to public health, complicating the treatment of bacterial infections and increasing morbidity, mortality, and healthcare costs. The rapid emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) pathogens, coupled with the phenomena of heteroresistance and bacterial persistence, presents significant challenges in combating AMR. These persister cells, capable of surviving antibiotic treatment without genetic resistance, contribute to chronic infections and relapses, making effective eradication even more difficult. Despite advancements in drug discovery, the pipeline for novel antibiotics remains limited, necessitating innovative strategies to optimize existing treatments and develop next-generation therapeutics. This issue will focus on novel and repurposed antibiotics, synergistic combination therapies, antimicrobial adjuvants, pharmacokinetic/pharmacodynamic (PK/PD) optimization, and non-traditional approaches such as bacteriophage therapy and anti-virulence strategies.

Guest Editors

Dr. Jan Naseer Kaur

Dr. Nicholas Smith

Dr. Parikshit Padhi

Deadline for manuscript submissions

closed (25 September 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/236268

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

